Cunningham Doug
Known title: President, EMEACIK: 0001883482
Associated companies
Transaction History
| KMB | ▼ Sell | Open Market | 3,833 | $524K | 5/10/2024 | View on chart |
| KMB | ▼ Sell | Open Market | 1,040 | $142K | 5/1/2024 | View on chart |
| KMB | ▲ Buy | Grant | 3,833 | $0 | 4/29/2024 | View on chart |
| KMB | ▲ Buy | Option Exercise | 1,040 | $0 | 4/26/2024 | View on chart |
| KMB | ▼ Sell | Open Market | 1,504 | $219K | 5/2/2023 | View on chart |
| KMB | ▲ Buy | Grant | 1,504 | $0 | 4/29/2023 | View on chart |
| KMB | ▼ Sell | Open Market | 4,242 | $581K | 5/3/2022 | View on chart |
| KMB | ▲ Buy | Option Exercise | 3,627 | $455K | 5/2/2022 | View on chart |
| KMB | ▼ Sell | Open Market | 3,627 | $501K | 5/2/2022 | View on chart |
| KMB | ▲ Buy | Option Exercise | 1,462 | $0 | 5/1/2022 | View on chart |
| KMB | ▲ Buy | Grant | 2,780 | $0 | 5/1/2022 | View on chart |
| KMB | ▲ Buy | Option Exercise | 1,554 | $195K | 4/25/2022 | View on chart |
| KMB | ▼ Sell | Open Market | 1,554 | $217K | 4/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Kimberly-Clark Guidance Reiterated as Sales Slip, Bond Sale Planned
Kimberly‑Clark confirmed its full‑year guidance even though recent sales were weaker than expected, which analysts at UBS said could help keep the stock stable. The company is also preparing a bond issuance to fund its planned purchase of a Tylenol‑making business. Shares have fallen about 13% and are trading near a long‑standing support level, while the dividend growth streak faces pressure. The mixed performance of consumer stocks and the stock’s inclusion in dividend‑focused lists add further context.
Kimberly-Clark Guidance Reiterated as Sales Slip, Bond Sale Planned. Kimberly‑Clark confirmed its full‑year guidance even though recent sales were weaker than expected, which analysts at UBS said could help keep the stock stable. The company is also preparing a bond issuance to fund its planned purchase of a Tylenol‑making business. Shares have fallen about 13% and are trading near a long‑standing support level, while the dividend growth streak faces pressure. The mixed performance of consumer stocks and the stock’s inclusion in dividend‑focused lists add further context.